31
Views
3
CrossRef citations to date
0
Altmetric
Review

Vaccines for HIV

&
Pages 1179-1188 | Published online: 25 Feb 2005

Bibliography

  • PIOT P: The science of AIDS: a tale of two worlds. (1998) 280(5370:1844–1845.
  • •The devastating effects of the HIV epidemic are difficult to overstate.
  • WAWER MJ, SEWANKAMBO NK, SERWADDA D et al:Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet (1999) 353 (9152):525–535.
  • STOTT EJ: Anti-cell antibody in macaques. Nature (1991) 353(6343)393.
  • ••Demonstration that simple, whole inactivated vaccines donot protect in an SIV model dampened initial enthusiasm for protein HIV vaccines.
  • MOOIJ P, BOGERS WM, OOSTERMEIJER H et al: Evidencefor viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Vim]. (2000) 74(9):4017–4027.
  • DANIEL MD, KIRCHHOFF F, CZAJAK Sc et al: Protective effects of a live attenuated SIV vaccine with a deletion in the nefgene. Science (1992) 258(50901938–1941.
  • ••High efficacy of live attenuated SW vaccines later subduedby ability of live attenuated vaccines to cause disease.
  • BABA TW, JEONG YS, PENNICK D et al: Pathogenicity oflive, attenuated SIVafter mucosal infection of neonatal macaques. Science (1995) 267 (5205):1820–1825.
  • LEARMONT JC, GECZY AF, MILLS J et al: Immunologicand virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl. J. Med. (1999) 340 (22):1715–1722.
  • DAVIS NL, CALEY IJ, BROWN KW et al: Vaccination ofmacaques against pathogenic simian immunodefi-ciency virus with Venezuelan equine encephalitis virus replicon particles. J Vim]. (2000) 74(1):371–378.
  • •Encouraging immunogenicity and efficacy demonstrated by recombinant Venezuelan equine encephalitis virus vectors against SIV.
  • HU SL, ABRAMS K, BARBER GN et al.: Protection of against SIV infection by subunit vaccines of envelope glycoprotein gp160. Science (1992)
  • •Demonstration that vaccinia-based HIV vaccine regimens could be protective against SIV. Later shown to be only partially protective.
  • WOLFF JA, MALONE RW, WILLIAMS P et al: Direct gene into mouse muscle in vivo. Science (1990) 247 (4949 Part1):1465–1468.
  • ••DNA vaccine field emerged with reports of protein expres-sion following naked DNA administration in vivo.
  • ROBINSON HL: DNA vaccines for immunodeficiency. AIDS (1997) 11 (Suppl.A):5109–119.
  • LU S, ARTHOS J, MONTEFIORI DC et al.: Simian immuno-deficiency virus DNAvaccine trial in macaques. J Vim]. (1996) 70 (6):3978–3991.
  • DAVIS HL, WEERATNA R, WALDSCHMIDT TJ et al.: CpG DNAis a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 160(2):870–876.
  • •Remarkable ability of adjuvant CpG DNA to enhance DNA vaccine-induced immunity demonstrated.
  • ANDRE S, SEED B, EBERLE J et al.: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Vim]. (1998) 72(2):1497–1503.
  • KENT SJ, ZHAO A, BEST SJ et al: Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus Type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Vim]. (1998) 72(12):10180–10188.
  • •Demonstration that DNA and poxvirus approaches were highly immunogenic. Partial protective efficacy later confirmed in pathogenic models.
  • HANKE T, SAMUEL RV, BLANCHARD TJ et al: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime- modified vaccinia virus Ankara boost vaccination regimen. j Vim/ (1999) 73 (9):7524–7532.
  • ROBINSON HL, MONTEFIORI DC, JOHNSON RP et al: Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations. Nature Med. (1999) 5(5):526–534.
  • ERON JJ, JR., ASHBY MA, GIORDANO MF et al.: Random-ised trial of MNrgp120 HIV-1 vaccine in symptomless 111V-1 infection. Lancet (1996) 348(9040:1547–1551.
  • •One of many failed therapeutic vaccine studies, mostly utilising protein vaccines.
  • ROSENBERG ES, BILLINGSLEY JM, CALIENDO AM et al: imr-1 -specific CD4+ T cell responses associ-ated with control of viremia. Science (1997) 278(5342):1447–1450.
  • CALAROTA S, BRATT G, NORDLUND S et al: Cellular response induced by DNA vaccination in-1 -in fectedpatients.Lancet(1998)351 (9112):1320–1325.
  • •First human DNA vaccine article published for any pathogen. Used here as a therapeutic vaccine for HIV with limited immunogenicity.
  • ARTHUR LO, BESS JW, JR., CHERTOVA EN et al: Chemical of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SW vaccine. AIDS Res. Hum. Retroviruses (1998) 14 (Supp1.3):S311–319.
  • •Novel inactivation of HIV-1 may retain greater immunogen-icity and shows promise as a new generation whole inacti-vated HIV vaccine.
  • MOOIJ P, VAN DER KOLK M, BOGERS WM et al: A clinically relevant HW-1 subunit vaccine protects macaques from in vivopassaged simian-human immunodeficiency virus infection. AIDS (1998) 12 (5):F15–22.
  • WYATT R, KWONG PD, DESJARDINS E et al: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 393 (6686):705–711.
  • KWONG PD, WYATT R, ROBINSON J et al.: Structure of an HEVgp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393 (6686):648–659.
  • •Crystal structure of HIV-1 gp120 demonstrated difficulties and potential opportunities, in the design of gp120-based vaccines that may induce neutralising antibodies.
  • LACASSE RA, FOLLIS KE, TRAHEY M et al: Fusion- vaccines: broad neutralization of primary of HIV. Science (1999) 283(5400357–362.
  • ••First convincing evidence that neutralising antibodies mightbe inducible utilising transient, conformational epitopes expressed during the HIV-1/cell fusion event.
  • CAFARO A, CAPUTO A, FRACASSO C et al: Control of1V-89.6P-infection of cynomolg-us monkeys by HIV-1 Tat protein vaccine. Nature Med. (1999) 5 (6):643–650.
  • •Tat, a small regulatory protein of HIV, shows promise as a vaccine antigen.
  • LEONG KH, RAMSAY AJ, MORIN MJ et al, Generation of enhanced immune responses by consecutive immuni-sation with DNA and recombinant fowlpox viruses. In: Vaccines 95. Brown F, Chanock H, Norrby E (Eds.), Cold Spring Harbour Laboratory Press, Cold Spring Harbor, USA (1995):327–331.
  • RAMSHAW IA, ANDREW ME, PHILLIPS SM et al: Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature (1987) 329:545–546.
  • •First demonstration of the remarkable immunostimulatory effect of encoding cytokines within recombinant vaccines; subsequently applied to HIV vaccines.
  • DEACON NJ, TSYKIN A, SOLOMON A et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 270(5238):988–991.
  • BERMAN PW, GRAY AM, WRIN T et al: Genetic and immunologic characterization of viruses infecting MN-rgp120- vaccinated volunteers. J. Infect. Dis. (1997) 176 (2):384–397.
  • CONNOR RI, KORBER BT, GRAHAM BS et al: Immuno-logical and virological analyses of persons infected by human immunodeficiency virus Type 1 while partici-pating in trials of recombinant gp120 subunit vaccines. J. Virol. (1998) 72(2):1552–1576.
  • KENT SJ, GREENBERG PD, HOFFMAN MC et al: Antago-nism of vaccine-induced HIV-1-specific CD4+Tcells by primary HIV-1 infection: potential mechanism of vaccine failure. J. Immunol. (1997) 158(2):807–815.

Websites

  • International AIDS Vaccine Initiative www.iavi.org (July 2000).
  • Joint United Nations Programme on HIV/AIDS www.unaids.org (July 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.